Unicef and Gavi lower malaria vaccine price by 40%
Summary and headline written by AI from the source article. How we work
Unicef and Gavi, a global vaccine group based in Geneva, Switzerland, agreed to reduce the price of the Mosquirix malaria vaccine by 40%.
The organizations expect this deal to save approximately $50 million (826 million South African rand) from 2027 to 2029, lowering the cost per dose to €5.50 (102 rand). GSK, which originally developed Mosquirix with the non-profit PATH, is transferring vaccine production to Bharat Biotech, an Indian drugmaker.
GSK will continue to provide a component needed for the vaccine until Bharat Biotech fully takes over production by 2028. The reduced price will begin in early 2027, contingent on regulatory approvals and Bharat Biotech receiving World Health Organization prequalification for its manufacturing facility. Last year, Gavi and Unicef also secured a 25% price cut for a different malaria vaccine produced by the Serum Institute of India.
